Palazestrant - OP1250

Based on 1 reference(s) in Google Scholar 8 10 1

Axon 4306

CAS [2092925-89-6]

MF C28H36FN3O
MW 449.60

  • Purity: 99%
  • Optical purity: 100% d.e.
  • Soluble in 0.1N HCl(aq), DMSO and EtOH
Recently added

Palazestrant

Description

Palazestrant is an orally bioavailable complete ER antagonist and selective ER degrader with an IC50 value of 6.4 nM (inhibition of E2 activity). Moreover, Palazestrant demonstrates antiproliferative activity in ER+ breast cancer models that is comparable or superior to other agents of interest.

KEYWORDS: Palazestrant | Supplier | ER antagonist/degrader | OP1250 | OP 1250 | OP-1250 | CAS [2092925-89-6] | Estrogen | Estrogen (ER) | Antagonist | Degrader | Receptors | ER-positive Breast Cancer | CERAN

Order
Size Unit Price Stock
5 mg €160.00 In Stock
25 mg €490.00 In Stock
Special Offers
Size Unit Price Stock
2 x 5 mg €240.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...